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Aims: Big endothelins (pro-endothelin; inactive-precursor) are converted to biologically active endothelins
(ETs). Mammals and humans produce three ET family members: ET-1, ET-2 and ET-3, from three different
genes. Although ET-1 is produced by vascular endothelial cells, these cells do not produce ET-3, which is pro-
duced by neuronal cells and organs such as the thyroid, salivary gland and the kidney. In patients with
end-stage renal disease, abnormal vascular endothelial cell function and elevated plasma ET-1 and big ET-1
levels have been reported. It is unknown whether big ET-2 and big ET-3 plasma levels are altered in these pa-
tients. The purpose of the present study was to determine whether endogenous ET-1, ET-2, and ET-3 systems
including big ETs are altered in patients with end-stage renal disease.
Main methods: We measured plasma levels of ET-1, ET-3 and big ET-1, big ET-2, and big ET-3 in patients on
chronic hemodialysis (n=23) and age-matched healthy subjects (n=17).
Key ﬁndings: In patients on hemodialysis, plasma levels (measured just before hemodialysis) of both ET-1 and
ET-3 and big ET-1, big ET-2, and big ET-3 were markedly elevated, and the increase was higher for big ETs
(Big ET-1, 4-fold; big ET-2, 6-fold; big ET-3: 5-fold) than for ETs (ET-1, 1.7-fold; ET-3, 2-fold).
Signiﬁcance: In hemodialysis patients, plasma levels of the inactive precursors big ET-1, big ET-2, and big ET-3
levels are markedly increased, yet there is only a moderate increase in plasma levels of the active products,
ET-1 and ET-3. This suggests that the activity of endothelin converting enzyme contributing to circulating
levels of ET-1 and ET-3 may be decreased in patients on chronic hemodialysis.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Endothelin-1 (ET-1) has potent and extremely long-lasting vasocon-
strictor effects (Yanagisawa et al., 1988). Several studies have demon-
strated that mammals and humans produce three distinct members
of the ET peptide families ET-1, ET-2 and ET-3, whichmay have different
proﬁles of biological activity on vascular and non-vascular tissues (Inoue
A et al., 1988; Yanagisawa and Masaki, 1989; Miyauchi and Masaki,
1999). Although ET-1 is produced by vascular endothelial cells, these
cells do not produce ET-3 (Inoue et al., 1989; Yanagisawa and Masaki,
1989; Bloch et al., 1989; Miyauchi and Masaki, 1999). ET-3 was found
to be located in the non-cardiovascular tissues including the porcine
brain and the cells outside the neurologic systems, therefore these
ﬁndings suggest that ET-3 plays several physiological roles including
neuropeptide functions (Shinmi et al., 1989; Miyauchi and Masaki,(Cardiology), Division of Clini-
a, Tsukuba, Ibaraki 305-8575,
uchi).
-NC-ND license.1999). Thus, ET-1 andET-3 are considered to possess different physiolog-
ical roles.
Big endothelin (pro-endothelin; the inactive precursor of
endothelin) is converted to endothelin, the active form of the peptide
with strong vasoconstrictor and vasoproliferative activity (Miyauchi
and Masaki, 1999). ET-1 is produced by vascular endothelial cells,
however, the vascular endothelium does not produce ET-3 (Inoue et
al., 1989; Yanagisawa and Masaki, 1989; Bloch et al., 1989;
Miyauchi and Masaki, 1999). There are two receptors for endothelins,
the ETA-receptor and the ETB receptor (Miyauchi and Masaki, 1999).
The afﬁnity for ETA receptors is greater for ET-1 than for ET-3, where-
as the afﬁnity of ETB receptors is equivalent for ET-1and ET-3
(Miyauchi and Masaki, 1999). Therefore, the ET-1/ETA system has
been speculated to be more important for cardiovascular regulation
than the ET-3/ETB system. Interestingly, exogenously applied big ET-3
was reported to constrict forearm resistance vessels in humans via con-
version to ET-3, the active form of the peptide (Ferro et al., 2000).
Currently, endothelin receptor antagonists, such as bosentan
(endothelin ETA/B receptor blocker; i.e., non-selective antagonist)
and ambrisentan (ETA receptor selective antagonist) are clinically ap-
plied in patients with pulmonary hypertension (Shimojo et al., 2009;
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ment of pulmonary hypertension (up to 125 mg/day [b.i.d]; systemic ar-
terial pressure does not decrease whereas pulmonary arterial pressure is
lowered (Shimojo et al., 2009; Baliga et al., 2011). Furthermore, it has
been reported that at higher doses endothelin antagonists are effective
in reducing also systemic blood pressure in humans (Krum et al., 1998;
Maeda et al., 2009). The pro-hypertensive effect of endothelin-1 is also
supported by animal studies, since it also has been reported that
endothelial-cell speciﬁc ET-1 over-expressing mice are hypertensive
(Leung et al., 2011), whereas that the endothelial-cell speciﬁc ET-1
deﬁcient mice are hypotensive (Kisanuki et al., 2010). This evidence
suggests that endogenous ET-1 generated in the vascular endotheli-
ummay participate in themodulation of the systemic blood pressure
in vivo.
In addition to systemic hypertension and ET-1, it has been
suggested that overexpression of ET-1 aggravates increases in blood
pressure under conditions such as a high salt diet (Amiri et al.,
2004, 2010). Amiri et al. reported that the endothelial
over-expression of ET-1 had no statistically signiﬁcant effect on the
total 24-hour blood pressure measurements of these mice (Amiri et
al., 2004), whereas these mice showed differences in blood pressure
at individual time points of the 24 h measurements (Amiri et al.,
2004) and were shown to become hypertensive if placed on a high
salt diet (Amiri et al., 2010).Moreover, Saleh et al. reported that chronic
ET-1 infusion in rats does not increase blood pressure, yet promotes in-
ﬂammation (Saleh et al., 2010).
It has been reported that ET-1 is involved in progression of renal
diseases (Hocher et al., 1997; Shindo et al., 2002). Hocher et al.
reported that ET-1 transgenic mice developed glomerulosclerosis, in-
terstitial ﬁbrosis, and renal cysts (Hocher et al., 1997). Shindo et al.
reported that the renal damage and salt-dependent hypertension
were observed in aged transgenic mice overexpressing ET-1 (Shindo
et al., 2002). Therefore, it has been considered that the ET systems
are involved in the progression of chronic renal failure. Indeed, it
has reported that plasma ET-1 levels are elevated in patients with
chronic hemodialysis (Koyama et al., 1989; Miyauchi et al., 1991;
Ottosson-Seeberger et al., 1999). However, it is unknown whether
plasma big ET-2 and big ET-3 levels are altered in patients on chronic
hemodialysis. We have previously established sandwich-enzyme
immunoassays (sandwich-EIAs) for ET-1 (Miyauchi et al., 1989),
ET-3 (Miyauchi et al., 1991; Maeda et al., 1997) and big ET-1, big
ET-2, and big ET-3 (Miyauchi et al., 1989; Suzuki et al., 1990,
1991). To study the potential pathophysiological role of the ET fam-
ily in human end-stage renal disease, we measured plasma levels of
ET-1, ET-3 and big ET-1, big ET-2, and big ET-3 in patients on chronic
hemodialysis and in age-matched healthy control subjects using the
sandwich-EIAs for each of the above peptides of the endothelin
family.Methods
Blood samples from normal subjects and patients
Blood samples were collected from antecubital veins of male pa-
tients undergoing chronic hemodialysis (n=23, 46±1.6 years of
age) and age-matched male healthy subjects (n=17, 45±1.8 years
of age). In hemodialysis patients, blood samples were drawn just be-
fore patients underwent hemodialysis. This study was reviewed and
approved by the Institutional Review Board at the University of Tsukuba,
and the subjects gave theirwritten informed consent to participate in the
study. Blood samples of hemodialysis patients were obtained from
Sumiyoshi Clinic Hospital. Each blood sample was put in chilled tubes
containing aprotinin (300 KIU/ml) and EDTA (2 mg/ml) and then
centrifuged at 2000×g for 15 min at 4 °C. The plasma was stored
at−30 °C until used.Extraction procedure
Plasma (1 ml) was acidiﬁed with 3 ml of 4% acetic acid, and immu-
noreactive ET-1, ET-3 or big ET-1, -2, and -3 were extracted with a
Sep-Pack C-18 cartridge (Waters Associates,Milford,MA, USA) as previ-
ously described (Miyauchi et al., 1989; Suzuki et al., 1990; Maeda et al.,
1997). The elutes were reconstituted with 0.25 ml of assay buffer and
subjected to the EIAs.Sandwich-EIAs
Sandwich-EIAs for ET-1 were carried out as previously described
using immobilized mousemonoclonal antibody AwETN40, which rec-
ognizes the N-terminal portion of ET-1, and peroxidase-labeled rabbit
anti-ET-1 C-terminal peptide (15-21) Fab' (Takeda Chemical Industry,
Tsukuba, Japan) (Miyauchi et al., 1989). In the sandwich-EIA for ET-3,
the monoclonal antibody AET-30, which recognizes the N-terminal
loop domain of ET-3, was used as an immobilized capture antibody
(Takeda Chemical Industry, Tsukuba, Japan) (Miyauchi et al., 1991;
Maeda et al., 1997). An antibody against the C-terminal heptapeptide
of ET-3, the sequence common to other endothelins, was elicited in
rabbits by immunizing animals with ET-3 (15–21)-BSA conjugates
(Takeda Chemical Industry, Tsukuba, Japan) (Miyauchi et al., 1991;
Maeda et al., 1997). The Fab fragment of this rabbit antibody was
used as an enzyme-labeled detector antibody after being coupled with
horseradish peroxidase (Miyauchi et al., 1991;Maeda et al., 1997). Sim-
ilarly, in the sandwich-EIA for big ET-1, immobilized AwET40 and
peroxidase-labeled rabbit anti-human big ET-1 C-terminal peptide
(22–38) Fab' was used (Takeda Chemical Industry, Tsukuba, Japan)
(Suzuki et al., 1990). Similarly, plasma big ET-2 and big ET-3 levels
were also measured by their sandwich EIAs according to previous re-
ports (Suzuki et al., 1991; Matsumoto et al., 1994). The assay for ET-1
does not cross-react with ET-3 or big ET-1 (cross-reactivity: b0.1%).
The assay for ET-3 does not cross-react with ET-1, big ET-1 or big ET-3
(cross-reactivity: b0.1%). The assay for big ET-2 does not cross-react
with big ET-1 or big ET-3 (cross-reactivity: b1.0%). The assay for
big ET-3 does not cross-react with big ET-1 or big ET-2 (cross-
reactivity: b1.0%). Thus, these sandwich-EIAs are sensitive enough to
detect 0.1–0.4 pg/well of the respective ETs or big ETs studied with a
high speciﬁcity due to a cross-reactivity of less than 1% with other ETs
and big ETs (Miyauchi et al., 1989; Suzuki et al., 1990, 1991; Matsumoto
et al., 1994; Maeda et al., 1997).Statistics
Data are expressed as mean±S.E.M. Statistical analysis was carried
out using the Student's t-test for unpaired comparisons. Differences
were considered statistically signiﬁcant at p values of b0.05.Results
In patients on chronic hemodialysis, peptide plasma of both ET-1,
ET-3, and big ET-1, big ET-2, and big ET-3-1 were signiﬁcantly higher
than those in healthy subjects (Fig. 1, Table 1) In patients on hemodi-
alysis, plasma levels (measured just before hemodialysis) of both
ET-1 and ET-3 and big ET-1, big ET-2, and big ET-3 were markedly
elevated, and the relative increase was higher for big ETs (big
ET-1, 4-fold; big ET-2, 6-fold; big Et-3, 5-fold, all pb0.05) than for
ETs ((ET-1, 1.7-fold; ET-3, 2-fold), all pb0.05)). Also, the relative
levels of the different big ET peptides were markedly different be-
tween healthy controls and renal disease patients, in which levels
were approx. 17 pg/ml (big ET-1), approx. 40 pg/ml (big ET-2) and
more than 70 pg/ml (big ET-3) (Fig. 1 and Table 1).
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Fig. 1. Plasma levels of big endothelins (big ET-1, big ET-2, and big ET-3) in healthy subjects (n=17; open columns) and patients on hemodialysis (n=23; ﬁlled columns). Note
different scales of the y axes in the three panels. Data are mean±SEM, ⁎pb0.05 vs healthy subjects.
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The present study demonstrates the novel ﬁnding that plasma
levels of big ET-2, and big ET-3 are markedly increased in patients
on hemodialysis, and therefore it was suggested that the elevation
in these peptides might be partly attributed to the increase in produc-
tion of mature ET peptides in hemodialysis patients that was also ob-
served. Since vascular endothelial cells produce ET-1 and big ET-1
(Miyauchi and Masaki, 1999), it has been suggested that production
of ET-1 in vascular endothelial cells was increased due the hemody-
namic overload in hemodialysis patients. Since vascular endothelial
cells do not produce ET-3 – but do produce ET-1 (Inoue et al., 1989;
Yanagisawa and Masaki, 1989; Bloch et al., 1989; Miyauchi and
Masaki, 1999) – it is possible that the elevation in plasma levels of big
ET-3 and ET-3 in hemodialysis patients can be in part attributed to a de-
creased clearance of these peptides due to renal insufﬁciency. The pres-
ent study demonstrates for the ﬁrst time that the plasma levels of big
ET-2 and big ET-3 aremarkedly increased in patientswith hemodialysis,
and also demonstrates that the relative intensity of the increase is
higher for big ET-3 (the inactive precursor with a 5-fold increase) com-
pared to ET-3 (mature active peptide, 2-fold increase). Therefore, it is
possible that the production of big ET-3 is increased whereas the con-
version of big ET-3 to ET-3 might be decreased in these patients. The
data also shows a 6-fold increase in plasma big ET-2 in hemodialysis pa-
tients. The increase in plasmabig ET-1 level in hemodialysis patients ob-
served in the present study is in accordance with a previous report
(Suzuki et al., 1990). Inasmuch as ET-3 may be a neuropeptide
(Shinmi et al., 1989; Miyauchi and Masaki, 1999), the elevation in plas-
ma ET-3 and big ET-3 levels in hemodialysis patients may suggest that
ET-3-mediated neuronal responses are altered in hemodialysis patients.
Moreover, the absence of ET-3 production in the vascular endothelium
would suggest that the ET-1/ETA system is likely to be more important
for cardiovascular regulation than the ET-3/ETB system. However, in
this context an interesting ﬁnding has been reported, namely that
exogenously applied big ET-3 causes constriction of forearm resis-
tance vessels in humans via conversion to ET-3, its converted, active
form (Ferro et al., 2000). Because it was reported that the high-doseTable 1
Plasma levels of endothelins (ET-1 and ET-3) in healthy subjects and patients on
hemodialysis.
ET-1 ET-3
Healthy subjects (n=17) 1.5±0.1 0.8±0.1
Patients on hemodialysis (n=23) 2.6±0.3⁎ 1.7±0.2⁎
⁎ pb0.05 vs healthy subjects. Values are pg/ml and given as mean±SEM.bosentan (ET-A/B dual receptor antagonist) causes a signiﬁcant decrease
in systemic blood pressure in healthy middle-aged and older adults
(Maeda et al., 2009), and in patients with essential hypertension
(Krum et al., 1998), it has been considered that the endogenous
endothelin systems is involved in regulation of the systemic blood pres-
sure in humans. Therefore, it is likely that both the endogenous ET-1/
ETA system and endogenous ET-3/ETB system may be differently in-
volved in regulation of blood pressure in normal subjects and hemodi-
alysis patients.
Plasma ET-1 levels are increased in various cardiovascular diseases
(Miyauchi andMasaki, 1999; Shimojo et al., 2009). ET-1 has been impli-
cated in the pathogenesis of arterial stiffening (McEniery et al., 2003).
McEniery et al. (2003) reported that the administration of ET-1 in-
creases arterial pulse wave velocity (PWV), a traditional index of re-
gional arterial stiffness, and treatment with an ET receptor antagonist
reduces PWV.We also reported that the directly-measured central arte-
rial compliance increased with ETA/B dual receptor blockade in humans
(Maeda et al., 2009).We found that arterial compliance increases signif-
icantly with the administration of ETA/B dual receptor blockade humans
(Maeda et al., 2009). Taken together, these results suggest that
endogenously produced ET-1 contributes to the regulation of arterial
stiffness and arterial compliance in the systemic circulation of humans.
We previously reported that exercise training reduces plasma ET-1
levels (Maeda et al., 2001, 2003, 2009). Therefore, exercise training pos-
sibly could be a useful therapy for reducing ET-1 levels, thereby improv-
ing cardiovascular diseases including chronic kidney disease (CKD).
In humans, plasma levels of ET-1 obtained fromperipheral vessels are
very low,much lower than those of ET-1 and ET-3 (Miyauchi et al., 1991;
Suzuki et al., 1991; Matsumoto et al., 1994). However, the present study
shows that apparently high circulating levels of big ET-2, a precursor of
ET-2, are present in patients with hemodialysis. This suggests that the
ET-2 system might play some pathophysiological roles of patients with
chronic hemodialysis. The present study also demonstrates that the
magnitude of increase in patients with hemodialysis was highest for
big ET-2 (6-fold increase), followed by big ET-3 (5-fold increase), and
big ET-1 (4-fold increase).
The observed changes of plasma levels of big endothelins in patients
with chronic kidneydisease suggest that ET-1 andET-3mayplay different
roles in acute and chronic alterations of blood pressure in hemodialysis
patients. Since plasma endothelin-like immunoreactivity has been re-
ported to be elevated in various disease states in humans (Miyauchi et
al., 1989; Masaoka et al., 1989; Cernacek and Stewart, 1989; Miyauchi
andMasaki, 1999), the ﬁndings of the present study suggest that concen-
trations of each endothelin (i.e., separately measured levels of ET-1 and
-3, and big ET-1, big ET-2, big ET-3) might be used as markers of disease
in renal patients andwhen studying the physiological/pathophysiological
roles of endothelin in human diseases.
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